Clinical Trials
48 trialsA Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis
Sun Yat-sen University
FANTASTIC
Sun Yat-sen University
IDEA
GERCOR - Multidisciplinary Oncology Cooperative Group
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
Cinnagen
Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial
Zhujiang Hospital
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial
Zhujiang Hospital
Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma
Sun Yat-sen University
ARMANI
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC
Sun Yat-sen University
HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B
Sun Yat-sen University
HAIC Versus Systemic Chemotherapy for Unresectable ICC
Sun Yat-sen University
A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer
1Globe Biomedical Co., Ltd.
Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)
Fudan University
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
Sun Yat-sen University
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
Sun Yat-sen University
Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer
Hellenic Oncology Research Group
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
Sun Yat-sen University
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
Sun Yat-sen University
FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients
Fudan University
Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection
Fudan University
Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma
Taichung Veterans General Hospital
A Multi-center Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer
Fudan University
A Study Comparing Adjuvant Chemotherapy Versus Observation for Patients With Rectal Adenocarcinoma After Neoadjuvant Chemo-Radiotherapy Treatment.
Instituto do Cancer do Estado de São Paulo
Panc001
AHS Cancer Control Alberta
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
Ludwig-Maximilians - University of Munich
Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
National Cancer Institute (NCI)
Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer
National Cancer Institute (NCI)
Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Colon Cancer
National Cancer Institute (NCI)
Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer
University of Southampton
A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer
Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer
Hokkaido Gastrointestinal Cancer Study Group
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
ICOG
Iwate Medical University
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.
Mast Therapeutics, Inc.